Galantamine transdermal patch shows higher tolerability over oral galantamine in rheumatoid arthritis rat model

Lamia Said Kandil, Amira Sayed Hanafy, Sherien A. Abdelhady

Research output: Contribution to journalArticlepeer-review

6 Citations (Scopus)


Rheumatoid arthritis (RA) is a chronic autoimmune disease of idiopathic etiology that triggers inflammatory cytokines compromising the joint mobility. Epidemiological evidences recommend the utilization of galantamine (GH) to reverse the anti-inflammatory reactions induced RA. Oral administration of GH is non-selectivity due to its association with serious gastrointestinal symptoms which, could hinder its therapeutic success. Therefore, the present study aimed to validate the therapeutic potential of GH transdermal patches as a novel application to constitute an effective and tolerable delivery system for managing RA in adjuvant arthritis model. RA was induced in Sprague-Dawley rats intradermally by Heat-killed M (0.12 ml/day). Oral GH (1.25 mg/kg/day) and GH transdermal patch (2.5 mg/kg/2 days) were administrated for 14 days, during which the hind paw and body weight (BW) were assessed. Effects of C-reactive protein (CRP), inflammatory cytokines (TNF-α, IL-10 and IL-1β) and Janus kinase (JAK-2) were evaluated. Oral- and transdermal GH significantly improved the hind paw edema in arthritis animal model and offered a protective impact against RA. Oral GH group showed marked decrease in BW than that of transdermal patches group. Transdermal patch group showed a significant decrease in the level of IL-1β more than the oral group. However, no significant difference was detected in the levels of TNF-α and IL-10 between the two groups. It is concluded that GH transdermal patch can be a promising drug delivery system that copes with side effects better than oral GH consequently represents novel strategy in management of RA.
Original languageEnglish
Pages (from-to)996-1004
Number of pages9
JournalDrug Development and Industrial Pharmacy
Issue number6
Early online date18 May 2020
Publication statusPublished - 2020


  • Rheumatoid arthritis
  • adjuvant-induced arthritis
  • complete Freund's adjuvant
  • galantamine
  • transdermal drug delivery

Cite this